ʻO Tirzepatide Injection no ka maʻi diabetes a me ke kaumaha

ʻO Tirzepatide kahi puke hou ʻelua glucose-dependent insulinotropic polypeptide (GIP) a me glucagon-like peptide-1 (GLP-1) receptor agonist i hoʻomohala ʻia. ʻO kāna hana ʻelua ka manaʻo e hoʻonui i ka huna ʻana o ka insulin, kaohi i ka hoʻokuʻu ʻana o ka glucagon, hoʻopaneʻe i ka hoʻokuʻu ʻana o ka ʻōpū, a hoʻomaikaʻi i ka māʻona, e hāʻawi ana i kahi ala lapaʻau piha no ka type 2 diabetes mellitus (T2DM) a me ka momona.

Nā ʻIke Koʻikoʻi mai ka Haʻawina Kauka

1. Hoʻoponopono Glycemic

Ma waena o nā mea he nuiOIHANAʻO ka pae 3 nā hoʻokolohua lapaʻau, hōʻike ʻia ʻo tirzepatideka mana glycemic kiʻekiʻei hoʻohālikelike ʻia me nā mea antidiabetic i loaʻa, me ka semaglutide a me ka insulin degludec.

• Mean HbA1c hoemi: a hiki i−2.4%mai ka papa kuhikuhi ma hope o 40-52 pule.

• Ua loaʻa kahi hapa kiʻekiʻe o nā mea komoHbA1c < 6.5%, hālāwai a ʻoi aku paha i nā pahuhopu ADA.

• Ua ʻike ʻia nā hoʻomaikaʻi koʻikoʻi o ka glucose plasma hoʻokēʻai a me nā pae glucose postprandial.

2. Hoemi Weight

Hana mau ʻia ʻo TirzepatideʻO ka hoʻohaʻahaʻa ʻana i ke kaumaha ma ke ʻano maʻima ka maʻi maʻi a me ka maʻi maʻi ʻole.

• I nā maʻi T2DM: ʻo ka awelika o ke kaumaha o ke kino mai7–12 kg.

• I loko o nā kumuhana obese non-diabetic (SURMOUNT-1 hoʻāʻo):

  • ʻO 10 mg a me 15 mg i alakaʻi ʻia iʻO 15-22% ka nui o ke kaumaha o ke kino, hoʻohālikelike a ʻoi aʻe paha i nā paepae o ke kaʻina hana bariatric.

• Loaʻa ka hapa nui o nā mea komo5–10%hoemi kaumaha.

3. Hoʻomaikaʻi Cardiometabolic

Ua hoʻomaikaʻi pū ka mālama ʻana iā Tirzepatide i nā ʻāpana metabolic ākea:

• Hoemii nā triglycerides, LDL-C, a me ka cholesterol holoʻokoʻa.

• Hoʻonuima HDL-C.

• Mea nuika emi ʻana o ke koko systolic a me ka diastolic.

• Hoʻomaikaʻi i ka ʻike insulin a me ka hana β-cell.

4. Ka palekana a me ka hoʻomanawanui

Ua kūlike ka ʻike palekana me nā lāʻau lapaʻau e pili ana i ka incretin:

• ʻO ka hapa nui o nā hopena ʻino: nā hōʻailona o ka maʻi maʻi maʻi a me ka haʻahaʻa (nausea, luaʻi, maʻi paʻi).

• ʻO ka haʻahaʻa haʻahaʻa o ka hypoglycemia, ka mea nui ke hoʻohana ʻia me ka insulin a i ʻole sulfonylureas.

• ʻAʻohe pilikia palekana koʻikoʻi i ʻike ʻia i nā hopena cardiovascular.

5. ʻIke Mechanistic

ʻO Tirzepatide kūikawāʻelua agonism hoʻokipahoʻonui i nā ala GIP a me GLP-1:

• Hoʻolaʻa GIPhoʻonui i ka huna ʻana o ka insulin e pili ana i ka glucose a hiki ke hoʻomaikaʻi i ka metabolism adipose tissue.

• Hoʻolaʻa GLP-1hoʻolalelale i ka hoʻokahe ʻana o ka ʻōpū.

• ʻO kā lākouhopena synergisticalakaʻi i ka hoʻomalu glucose hoʻomaikaʻi ʻia me ka hoʻemi ʻana i ke kaumaha i hoʻohālikelike ʻia me nā mea ala ala hoʻokahi.

Ka hopena

Hōʻike ʻo Tirzepatide i kahiholomua i ka metabolic therapy, hoolako anaʻO ka hopena maikaʻi ʻole i ka mana glycemic a me ka hōʻemi kaumahano nā poʻe me ka maʻi diabetes type 2 a me ka momona.
Hāʻawi kāna hana ʻelua incretin i kahi ala hoʻohui e hoʻoponopono ai i nā kumu kumu o ka metabolic dysfunction - hyperglycemia, insulin resistance, a me ke kaumaha o ke kino.
Hāʻawi ʻia i kāna ʻano ikaika a me ka ʻike palekana palekana, hiki i ka tirzepatide ke hoʻololi hou i ka paradigm therapeutic no ka maʻi diabetes a me ka hoʻokele obesity i nā makahiki e hiki mai ana.

Nā kuhikuhi

• Frias JP et al.,ʻO ka New England Journal of Medicine, 2021.

• Jastreboff AM et al.,ʻO ka New England Journal of Medicine, 2022 (SURMOUNT-1).

• Ludvik B et al.,Lancet, 2021.

• ʻIkepili Kālā Eli Lilly, SURPASS Nā Hoʻāʻo 1–5.